{"entity":{"id":"medpacto","kind":"company","name":"MedPacto","aka":["MedPacto Inc.","메드팩토","KOSDAQ:235980"],"tldr":"MedPacto is a South Korean biotech whose oral TGF-beta receptor inhibitor vactosertib is being tested with chemotherapy and checkpoint inhibitors in colorectal, stomach and bone-marrow cancers.","summary":"MedPacto, listed on KOSDAQ, develops vactosertib (TEW-7197), an oral inhibitor of the TGF-beta type 1 receptor kinase ALK5 that aims to relieve the immunosuppressive and fibrotic effects of TGF-beta in the tumour microenvironment. Vactosertib is in a phase 2/3 trial with FOLFIRI and bevacizumab in second-line metastatic colorectal cancer and has been studied with pembrolizumab in colorectal and gastric cancer, with pomalidomide in multiple myeloma and in osteosarcoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.medpacto.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["vactosertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"biotech","website":"https://www.medpacto.com/","ticker":"KOSDAQ:235980","stage":"public","investors":[],"funding":[]},"route":"/companies/medpacto/","neighbours":{"drug":[{"id":"vactosertib","kind":"drug","name":"Vactosertib","route":"/drugs/vactosertib/"}]}}